1,050 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
Q1 Earnings Spigot Opens: JNJ, BAC, UNH & More http://www.zacks.com/stock/news/381535/q1-earnings-spigot-opens-jnj-bac-unh-more?cid=CS-ZC-FT-381535 Apr 16, 2019 - This is the first "full week" of Q1 earnings season, though the influx of reports hitting the tape in the next few weeks to come will be even heavier.
J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer http://www.zacks.com/stock/news/380671/jjs-erdafitinib-gets-fda-approval-for-urothelial-cancer?cid=CS-ZC-FT-380671 Apr 15, 2019 - FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid Choice http://www.zacks.com/stock/news/379548/looking-for-a-growth-stock-3-reasons-why-johnson-johnson-jnj-is-a-solid-choice?cid=CS-ZC-FT-379548 Apr 12, 2019 - Johnson & Johnson (JNJ) could produce exceptional returns because of its solid growth attributes.
What's in Store for Dow ETF in Q1 Earnings? http://www.zacks.com/stock/news/378730/whats-in-store-for-dow-etf-in-q1-earnings?cid=CS-ZC-FT-378730 Apr 11, 2019 - Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.
Alkermes Reports Positive Data From Schizophrenia Study http://www.zacks.com/stock/news/377786/alkermes-reports-positive-data-from-schizophrenia-study?cid=CS-ZC-FT-377786 Apr 10, 2019 - Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
5 Stocks to Prepare for a Global Economic Slowdown http://www.zacks.com/stock/news/376479/5-stocks-to-prepare-for-a-global-economic-slowdown?cid=CS-ZC-FT-376479 Apr 10, 2019 - In such an event, demand for products and services generated by utilities, consumer staples and medical companies remain invariant.
Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients http://www.zacks.com/stock/news/372924/glaxos-dovato-gets-fda-nod-for-treatment-naive-hiv-patients?cid=CS-ZC-FT-372924 Apr 09, 2019 - Glaxo's (GSK) ViiV Healthcare gets FDA approval for a single-tablet two-drug regimen (2DR), Dovato for treatment naive HIV- 1 adults.
Aeglea (AGLE) Reports New Positive Data for Pegzilarginase http://www.zacks.com/stock/news/372396/aeglea-agle-reports-new-positive-data-for-pegzilarginase?cid=CS-ZC-FT-372396 Apr 08, 2019 - Aeglea (AGLE) reports new positive data for pegzilarginase in patients with Arginase 1 Deficiency.
Company News For Apr 8, 2019 http://www.zacks.com/stock/news/372304/company-news-for-apr-8-2019?cid=CS-ZC--372304 Apr 08, 2019 - Companies In The News Are: BA, ABMD, TGI, C, JNJ

Pages: 12345678...105

<<<Page 3>